How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

Canadian Journal of Cardiology

Volumn 24, Issue 5, 2008, Pages 363-368

  Grima, Daniel T ^a   Leiter, Lawrence A ^b   Goodman, Shaun G ^b,c   Attard, Cheryl L ^a   Chow, Chi Ming ^b   Langer, Anatoly ^b,c  

^a Cornestone Research Group Inc ^*  (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN HEART RESEARCH CENTRE   (Canada)

Author keywords

ACE inhibitors; Acetylsalicylic acid; Canadian health care system; Death; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEALTH CARE SYSTEM; HEALTH SURVEY; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; REGISTER; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; STROKE; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CANADA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 44949201647     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70597-X     Document Type: Article

References (40)

1. Johansen H, Thillaiampalam S, Nguyen D, Sambell C. Diseases of the circulatory system - hospitalization and mortality. Health Rep 2005;17:49-53.
2. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: Nested case-control analysis. BMJ 2005;330:1059-63. (Erratum in 2006;332:912).
3. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2).
5. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4. (Erratum in 2003;169:1149).
6. 2005 CHEP Recommendations. (Version current at March 28, 2008).
7. Abramson BL, Huckell V, Anand S, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society Consensus Conference: Peripheral arterial disease - executive summary. Can J Cardiol 2005;21:997-1006.
8. Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality. Am Heart J 2006;151:969-75.
9. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG; Vascular Protection registry investigators. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. Am Heart J 2004;148:1028-33.
10. Yan AT, Yan RT, Tan M, et al; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: Targets still not met. Am J Med 2006;119:676-83.
11. Chow CM, Donovan L, Manuel D, Johansen H, Tu JV; Canadian Cardiovascular Outcomes Research Team. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005;21:1265-71.
12. Centers for Disease Control and Prevention (CDC). Self-reported heart disease and stroke among adults with and without diabetes - United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2003;52:1065-70.
13. Statistics Canada. Canadian Community Health Survey (CCHS) - cycle 2.1 (2003). Ottawa: Statistics Canada, 2004.
14. Statistics Canada, CANSIM table (for fee) 051-0001. Last modified 2005-10-27.
15. Statistics Canada, CANSIM, table (for fee) 052-0004 and Catalogue no. 91-520-X. Last modified 2005-12-21.
16. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272-81. (Erratum in 2002;143:21).
17. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
18. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991;22:312-8.
19. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham Study. Stroke 1982;13:290-5.
20. Kuntz KM, Weinstein MC. Modeling in economic evaluation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press, 2001.
21. Statistics Canada, 2006. Life Tables, Canada, Provinces and Territories 2000-2002. Statistics Canada Catalogue No. 84-537-XIE. Ottawa.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:23-33.
23. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. (Erratum in 2002;324:141).
24. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 2000;342:1376, 2000;342:748).
25. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: A cost-effectiveness analysis. Lancet 2006;368:679-86.
26. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 2006;144:326-36.
27. Hux JE, Booth GL, Slaughter PM, Laupacis A. Diabetes in Ontario: An ICES Practice Atlas. Institute for Clinical Evaluative Sciences, 2003.
28. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study. Diabet Med 2005;22:554-62.
29. UKPDS Risk Engine Version 2.0. (Version current at March 28, 2008).
30. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9. (Erratum in 2002;102:679).
31. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
32. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6.
33. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: Clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9.
34. Alter DA, Khaykin Y, Austin PC, Tu JV, Hux JE. Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: Do physicians undertreat? Diabetes Care 2003;26:1427-34.
35. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171:1189-92.
36. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence. Am Heart J 2003;145:438-44.
37. Shah BR, Mamdani M, Jaakkimainen L, Hux JE. Risk modification for diabetic patients. Are other risk factors treated as diligently as glycemia? Can J Clin Pharmacol 2004;11:e239-44.
38. Pilote L, Beck CA, Karp I, et al; Canadian Cardiovascular Outcomes Research Team. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 2004;20:61-7.
39. Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med 2004;164:40-4.
40. ISPOR Real World Task Force. Using Real World Data For Coverage And Payment Decisions: The ISPOR Real World Data Task Force Report. (Version current at March 28, 2008).